文献速递白血病MDS 与骨髓增殖性肿瘤浆细胞疾病

CYAD-01(一种基于NKG2D的自体CAR T细胞疗法)治疗复发或难治性急性髓系白血病、骨髓增生异常综合征或多发性骨髓瘤(THINK):1期试验剂量递增部分的血液学队列

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
PubMed 文献 · Lancet Haematol · 2023-02-07

THINK是一项多中心、开放标签、剂量递增的1期研究,评估无预处理或桥接化疗的CYAD-01多 infusion方案治疗复发/难治性急性髓系白血病、骨髓增生异常综合征或多发性骨髓瘤。16例患者接受治疗,7例(44%)出现3/4级治疗相关不良事件,5例(31%)出现3/4级细胞因子释放综合征,未达最大耐受剂量。12例可评估急性髓系白血病或骨髓增生异常综合征患者中3例(25%)客观缓解,2例急性髓系白血病缓解后桥接异基因造血干细胞移植并持续缓解。

要点

  • CYAD-01多 infusion方案无预处理治疗耐受性良好,未达最大耐受剂量。
  • 12例可评估急性髓系白血病或骨髓增生异常综合征患者中3例(25%)客观缓解。
  • 2例急性髓系白血病缓解后桥接异基因造血干细胞移植,持续缓解5和61个月。

核心结论

  • 无预处理的多 infusion CYAD-01方案耐受性良好并显示抗白血病活性,但在未桥接异基因造血干细胞移植的患者中无持久性。
  • 这些1期数据支持靶向NKG2D配体的CAR T细胞疗法的概念验证。
  • 需要进一步临床研究NKG2D-based CAR T细胞,可能通过组合抗原靶向方法提高抗肿瘤活性。

研究设计与样本

  • THINK研究为多中心、开放标签、剂量递增1期研究,纳入至少接受过一线治疗的复发或难治性急性髓系白血病、骨髓增生异常综合征或多发性骨髓瘤患者。
  • 患者来自美国和比利时的五家医院。
  • 剂量递增部分评估三个剂量水平:3×10^8(剂量水平一)、1×10^9(剂量水平二)和3×10^9(剂量水平三)细胞/次 infusion,采用3+3 Fibonacci设计,schedule为三次 infusion间隔2周,随后可能接受三次额外 infusion的巩固治疗。
  • 主要终点为总治疗患者人群中CYAD-01 infusion后剂量限制性毒性的发生。
  • 试验注册于ClinicalTrials.gov(NCT03018405)和EudraCT(2016-003312-12),已完成。

主要发现

  • 2017年2月6日至2018年10月9日,血液学剂量递增部分共登记25例患者,7例因产量不足生产失败,2例筛选失败,16例接受CYAD-01治疗。
  • 16例治疗患者中:剂量水平一3例多发性骨髓瘤和3例急性髓系白血病;剂量水平二3例急性髓系白血病;剂量水平三6例急性髓系白血病和1例骨髓增生异常综合征。
  • 中位随访118天(IQR 46-180)。
  • 7例(44%)出现3或4级治疗相关不良事件;所有剂量水平共5例(31%)出现3或4级细胞因子释放综合征;剂量水平三报告1例细胞因子释放综合征的剂量限制性毒性。
  • 无治疗相关死亡,未达最大耐受剂量;12例可评估复发或难治性急性髓系白血病或骨髓增生异常综合征患者中3例(25%)客观缓解。

临床怎么用

  • 作者认为,无预处理的多 infusion CYAD-01方案耐受性良好并显示抗白血病活性,但在未桥接异基因造血干细胞移植的患者中无持久性。
  • 作者认为,这些1期数据支持靶向NKG2D配体的CAR T细胞疗法的概念验证。
  • 作者认为,需要进一步临床研究NKG2D-based CAR T细胞,可能通过组合抗原靶向方法提高抗肿瘤活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which binds eight ligands that are overexpressed in a wide range of haematological malignancies but are largely absent on non-neoplastic cells. Initial clinical evaluation of a single infusion of CYAD-01 at a low dose in patients with relapsed or refractory acute myeloid leukaemia, myelodysplastic syndromes, and multiple myeloma supported the feasibility of the approach and prompted further evaluation of CYAD-01. The aim of the present study was to determine the safety and recommended phase 2 dosing of CYAD-01 administered without preconditioning or bridging chemotherapy. METHODS: The multicentre THINK study was an open-label, dose-escalation, phase 1 study for patients with relapsed or refractory acute myeloid leukaemia, myelodysplastic syndromes, or multiple myeloma, after at least one previous line of therapy. Patients were recruited from five hospitals in the USA and Belgium. The dose-escalation segment evaluated three dose levels: 3 × 108 (dose level one), 1 × 109 (dose level two), and 3 × 109 (dose level three) cells per infusion with a 3 + 3 Fibonacci study design using a schedule of three infusions at 2-week intervals followed by potential consolidation treatment consisting of three additional infusions. The occurrence of dose-limiting toxicities post-CYAD-01 infusion was assessed as the primary endpoint in the total treated patient population. The trial was registered with ClinicalTrials.gov, NCT03018405, and EudraCT, 2016-003312-12, and has been completed. FINDINGS: Between Feb 6, 2017, and Oct 9, 2018, 25 patients were registered in the haematological dose-escalation segment. Seven patients had manufacturing failure for insufficient yield and two had screening failure. 16 patients were treated with CYAD-01 (three with multiple myeloma and three with acute myeloid leukaemia at dose level one; three with acute myeloid leukaemia at dose level two; and six with acute myeloid leukaemia and one with myelodysplastic syndromes at dose level three). Median follow-up was 118 days (IQR 46-180). Seven patients (44%) had grade 3 or 4 treatment-related adverse events. In total, five patients (31%) had grade 3 or 4 cytokine release syndrome across all dose levels. One dose-limiting toxicity of cytokine release syndrome was reported at dose level three. No treatment-related deaths occurred, and the maximum tolerated dose was not reached. Three (25%) of 12 evaluable patients with relapsed or refractory acute myeloid leukaemia or myelodysplastic syndromes had an objective response. Among responders, two patients with acute myeloid leukaemia proceeded to allogeneic haematopoietic stem-cell transplantation (HSCT) after CYAD-01 treatment, with durable ongoing remissions (5 and 61 months). INTERPRETATION: Treatment with a multiple CYAD-01 infusion schedule without preconditioning is well tolerated and shows anti-leukaemic activity, although without durability outside of patients bridged to allogeneic HSCT. These phase 1 data support the proof-of-concept of targeting NKG2D ligands by CAR T-cell therapy. Further clinical studies with NKG2D-based CAR T-cells are warranted, potentially via combinatorial antigen targeted approaches, to improve anti-tumour activity. FUNDING: Celyad Oncology.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Sallman DA, Kerre T, Havelange V, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023. PMID: 36764323. doi:10.1016/S2352-3026(22)00378-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。